Imagion Biosystems Limited

ASX:IBX Stock Report

Market Cap: AU$11.3m

Imagion Biosystems Valuation

Is IBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of IBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate IBX's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate IBX's future cash flow value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IBX?

Key metric: As IBX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IBX. This is calculated by dividing IBX's market cap by their current book value.
What is IBX's PB Ratio?
PB Ratio-5x
Book-AU$2.16m
Market CapAU$11.28m

Price to Book Ratio vs Peers

How does IBX's PB Ratio compare to its peers?

The above table shows the PB ratio for IBX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.7x
AT1 Atomo Diagnostics
3.4xn/aAU$23.5m
DVL dorsaVi
5.3xn/aAU$32.7m
CBL Control Bionics
3.2xn/aAU$24.7m
MX1 Micro-X
7.1x107.62%AU$41.4m
IBX Imagion Biosystems
n/an/aAU$11.3m

Price-To-Book vs Peers: IBX has negative equity and a Price-To-Book Ratio (-5x) compared to the peer average (4.7x).


Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data


Price to Book Ratio vs Industry

How does IBX's PB Ratio compare vs other companies in the AU Medical Equipment Industry?

0 CompaniesPrice / BookEstimated GrowthMarket Cap
No more companies available in this PB range
IBX is unprofitableIndustry Avg. 3.4xNo. of Companies5PB0246810+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IBX has negative equity and a Price-To-Book Ratio (-5x) compared to the Australian Medical Equipment industry average (3.4x).


Price to Book Ratio vs Fair Ratio

What is IBX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IBX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IBX's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 08:30
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imagion Biosystems Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.